FAP
Prolyl endopeptidase FAP
As of the edition of 20 October 2026, FAP (prolyl endopeptidase FAP, UniProt Q12884) has 5 drugs tested at it and 3 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q12884
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 4
- Disease areas
- Cancer; Lungs and airways; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive; Digestive system
- Registered trials of its drugs
- 12
Drugs at this target
| Status | Count |
|---|---|
| Active | 2 |
| Stopped | 2 |
| Status not established | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Simlukafusp alfa | Active | Phase 3 | none listed |
| F19 131I | Stopped | Phase 2 | none listed |
| OMTX705 | Active | Phase 1 | none listed |
| RO7300490 | Status not established | Phase 1 | none listed |
| Sibrotuzumab | Stopped | Phase 1 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 2 |
| Total on the list | 3 |
| Company | Route |
|---|---|
| Boehringer Ingelheim | Route A |
The other 2 companies at FAP
In the product3 companies in all; 2 are not named here, and no score is.
See the 3 companies at FAP, ranked, with the facts behind eachRequest access. Nothing is shown until you do.